Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) Strikes a Marketing and Distribution Deal with Subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA

For more than 80 years, Merck has been playing a phenomenal role to combat infectious diseases. The company has put so much effort into the development of novel medicines. To scale even higher, Merck & Co., Inc. (NYSE:MRK) has deployed its subsidiary Kenilworth, N.J., the USA to work with Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV). The agreement entails marketing, selling, and distributing SIVEXTRO in the United States and other selected territories.

The agreement will run till December 31, 2023, with a possible renewal of three-year extensions. According to Nabriva’s CEO, Ted Schroeder, this is one of the significant moves that will benefit patients and the company’s shareholders and corporate strategy. SIVEXTRO is a treatment for acute bacterial skin and skin structure infections in adults and pediatric children of 12 years of age.

Community-Based Commercial and Sales Services For SIVEXTRO

The exclusive agreement is expected to generate added revenue to Nabriva. Its shares already surged more than 50% in pre-market trading after the publication of the agreement. Meanwhile, the company has also reached out to Amplity Health, which will offer community-based sales services. The pharmaceutical organization will help in building a flexible and scalable infrastructure to optimize the uptake of SIVEXTRO.

With the developing COVID-19 pandemic, which has thrown the whole world into a panic mode, Nabriva is not taking chances. Hence, it will be preparing clinicians by equipping them with the necessary information about the attributes of oxazolidinone-class antibacterial.

Approval of Intravenous (IV) Formulations of XENLETA by Health Canada

Sunovion Pharmaceuticals Canada Inc., Nabriva’s partner, has received approval from Health Canada to market XENLETA. The semi-synthetic pleuromutilin antibiotic is as effective as moxifloxacin as per the Leap 1 trial. It also exhibited sustainable efficacy in the Leap 2 trial and was declared a potential treatment for community-acquired bacterial pneumonia. However, it should only be used to treat or prevent proven infections and those alleged to be caused by susceptible bacteria.

In recent years, there has been a decline in the effectiveness of various antibiotics due to their resistance and cross-resistance. As a result, the marketplace does not have enough treatment options for serious infections, and the patients have turned to more toxic antibiotics.